Genomic gains and losses play a crucial role in the development of diffuse large B-cell lymphomas. High resolution array comparative genomic hybridization provides a comprehensive view of these genomic imbalances but is not routinely applicable. We developed a polymerase chain reaction assay to provide information regarding gains or losses of relevant genes and prognosis in diffuse large B-cell lymphomas.
Introduction
Diffuse large B-cell lymphomas (DLBCL) account for approximately one third of all non-Hodgkin's lymphomas in Western countries. 1 These neoplasms have a common aggressive clinical behavior but display great heterogeneity. The underlying molecular basis of this heterogeneity was partially elucidated by gene expression profiling studies that identified three major subgroups of DLBCL, termed germinal center B-cell-like DLBCL (GCB-DLBCL), activated B-cell-like DLBCL (ABC-DLBCL) and primary mediastinal DLBCL. 2, 3 Malignant lymphomas, and especially DLBCL, are genetically characterized by recurring translocations, such as t(3;14)(q27;q32), t(8;14) (q24;q32), or t(14;18)(q32;q21), deregulating the BCL6, MYC and BCL2 genes respectively as a result of their juxtaposition to immunoglobulin genes. 4 Transgenic mouse models with deregulated expression of BCL6 or MYC develop tumors displaying features of DLBCL or human Burkitt's lymphoma respectively. 5, 6 However, aberrant expression of BCL2 is not sufficient in mice for full lymphoma transformation and t(14;18) or t (3;14) are observed in non-tumoral B cells, indicating that accumulation of other genetic alterations is required for the malignant transformation. 7, 8 Array-based comparative genomic hybridization (array CGH) has the potential to detect these additional aberrations that play an important role in the development and progression of lymphomas. Using this approach, it was shown that recurrent genomic imbalances are related to the cell of origin or correlated with the prognosis. [9] [10] [11] [12] However, an array-CGH approach is not routinely applicable. By contrast, quantitative multiplex polymerase chain reaction of short fluorescent fragments (QMPSF) is an inexpensive and sensitive method for the detection of genomic deletions or duplications based on the simultaneous amplification of short genomic fragments using dye-labeled primers under quantitative conditions. [13] [14] [15] Using this approach, we determined gain/loss frequencies of several targeted genes and built a biological score able to predict the outcome of DLBCL independently of the International Prognostic Index.
Design and Methods

Patients
Seventy-seven patients diagnosed with a DLBCL (76 nodal cases and one extra-nodal case) followed in our institution were selected. This study was approved by the ethics committee of our institution. The inclusion criteria were the availability of appropriate paraffin embedded-tissues, available tumor DNA at the time of diagnosis from fresh or frozen tissues and complete clinical data. The median age of the patients was 58 years (range, 17 to 87 years). The distribution according to International Prognostic Index scores was as follow: scores 0-1=27 (36%); 2-3 = 30 (40%); 4-5 = 18 (24%). All patients received an anthracycline-containing combination of chemotherapy, including CHOP (40%) or intensified CHOP (39%) regimens. Eight patients received rituximab combined with chemotherapy as first line treatment and 13 received intensified chemotherapy with autologous stem cell transplantation in first response.
Array CGH
The CGH analysis was performed using a high resolution 60-mer oligonucleotide-based microarray that contains ~43,000 probes, with an average spatial resolution of 35 kB (Human genome CGH array 44B, Agilent Technologies, CA, USA). High molecular weight DNA was prepared using the standard method. Restriction was performed as recommended by the manufacturer of the arrays. Tumor DNA was labeled with cyanine-5 (Cy5) and reference DNA (pooled normal DNA, Promega, Madison, WI, USA) was labeled with cyanine-3 (Cy3). To increase the probability of detecting relevant genomic gains or losses involving candidate genes related to the outcome of DLBCL, CGH was performed in 17/77 cases selected on the basis of their particularly unfavorable outcome. The analyses of microarray images were performed with the Agilent CGH analytics 3.4.27 software. Classification as gain or loss was based on identification as such by the CGH plotter and visual inspection of the log2 ratios. Signal log2 ratios greater than 0.25 or less then -0.25 were considered to indicate gains and losses, respectively.
QMPSF assay
QMPSF is a sensitive method for detecting genomic deletions or duplications based on the simultaneous amplification of short genomic fragments using dyelabeled primers under quantitative conditions (patent FR 020924). 13, 14, 16 Polymerase chain reaction (PCR) products were analyzed on a sequencing platform used in the fragment analysis mode in which both peaks heights and areas are proportional to the quantity of template present for each target sequence. We designed two distinct QMPSF assays which contain the following target genes: Assay 1 -MYC (8q24), TP53 (17p13), CDKN2A (9p21), SIM1 (6q16) and CDKN1B (12p13.1); Assay 2 -c-REL (2p13), BCL6 (3q27), PTPRK (6q22), BCL2 (18q21) and MDM2 (12q15). The CECR1 gene, located at 22q11 was chosen as a reference gene, considering the fact that it appears uncommonly affected by aneuploidy or focal gains or losses in our own cytogenetic database and in published DLBCL series. 12, 17, 18 Primer pairs were designed for each of these 11 genes to generate PCR fragments ranging from 150 to 250 base pairs and chosen in a way that they do not encompass polymorphisms (Online Supplemental Table S1 ). PCR were run from 100 ng of genomic DNA in a final volume of 25 µL with 0.16 mmol/L of each deoxynucleoside triphosphate, 1.5 mmol/L MgCl2, 1 unit of thermoprime Plus DNA polymerase (AB gene, Epson, United Kingdom), 5% DMSO and 0.5 to 1.6 µmol/L of each primer, one primer of each pair carrying a 6-FAM label. After initial denaturation for 3 min at 94°C, 20 cycles were performed consisting of denaturation, 94°C for 15 sec, annealing 90°C for 15 sec (ramping 3°C/sec) and extension 70°C, 15 sec (ramping 3°C/sec, followed by a final extension step for 5 min at 70°C). Two control DNA were used (commercial DNA, Roche and a DNA extracted from a reactive lymph node) to calculate the mean normal/tumoral peak height ratio. Using this approach, we demonstrated that TP53 and MDM2 somatic defects could be reliably detected when the proportion of tumoral cells was as low as 20%. 15 In addition, polymorphic gene copy number changes were excluded in some cases using matched non-tumoral DNA as control.
QMPSF validation
Considering array-CGH as the reference method, QMPSF and array CGH were both performed in 17 cases. A correlation between CGH log2 and QMPSF ratio was established and allowed the sensitivity, specificity, positive and negative predictive values of the QMPSF assay to be determined. To determine the reliable QMPSF ratio for detecting gene gains or losses, the equation of the regression curve obtained was used to deduce the QMPSF ratio cut-offs corresponding to a CGH log2 ratio of -0.25 (loss) and +0.25 (gain).
TP53 mutational status
To investigate the frequency of TP53 mutations, the highly conserved exons 5 to 8 (central core domain) were screened for the mutation, as described elsewhere.
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Immunohistochemistry
Immunohistochemical studies were performed on formalin-fixed, paraffin-embedded tissue sections of lymph node (n = 76) or spleen tissue (n = 1) using antibodies directed against BCL2, p53 (Dako), BCL6, p27 (Novacastra), p16 (Biocare Medical), and c-REL (Calbiochem). Cases were classed as expressing BCL2 and c-REL if the protein was detected in > 50% tumor cells, and p27 and p16 positive if the protein was detected in > 10% tumor cells. GCB and non-GCB phenotypes were defined using the decision tree established by Hans with the same cut-offs.
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Statistic analysis
The linear relationship between QMPSF ratio and CGH fluorescence ratio was established using Pearson's coefficient (R). Overall survival was measured from the time of diagnosis to the date of death or last follow-up alive. Progression-free survival was calculated from the initiation of the treatment to the date of relapse, progression or death from any cause. Progression-free survival and overall survival rates were estimated by the Kaplan-Meier method and statistical differences were assessed by the log-rank test. A Fisher's exact test was used to evaluate the unequal distribution of the different genetic abnormalities and the GCB/ non-GCB phenotype and to correlate protein expression and allelic status. A multivariate analysis using a Cox model was conducted to assess the independent prognostic influence of the International Prognostic Index and QMPSF score. Analyses were performed using StatView ® and SEM software.
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Results
Array CGH
Chromosomal alterations were observed in all cases. The most frequent imbalances were loss of 7q31.33 (60%), loss of 9p21 (60%), loss of 14q23.1 (60%), loss of 14q23.1 (60%), loss of 13q33.3 (50%) loss of 6q14-q22 (50%), loss of 5q12.3 (40%), loss of 17p13.2 (25%), loss of 2q24 (35%), gains of 18q21.2 (60%) and 18q22.3 (30%), gain of 1q21-23 (50%), gain of 19q13.33-q13.41 (40%), gain of chromosome 12 (40%), gain of 2p14-p16 (25%), gain of 6p (25%), and gain of 8q24.12-q24.21 (20%) (Online Supplemental Figure S1 ).
QMPSF assays
QMPSF and CGH experiments were both performed in 17 cases ( Figure 1 ). The linear correlation between CGH log2 ratio and QMPSF ratio is illustrated in Figure  2A . The R 2 coefficient was 0.70, indicating a good concordance between the results of the two experiments. From the curve equation, a gene loss, defined by a mean CGH log2 ratio < -0.25, corresponds to a QMPSF ratio below 0.83. A gain detected by a mean CGH log2 ratio > +0.25 corresponds to a QMSPF ratio above 1.13. To maximize detection of true losses and gains, the ratio values finally used were 0.7 and 1.2, respectively. With these cut-offs, DNA copy number changes were confirmed in 156/170 amplicons, giving an overall concordance rate of 92%. The positive and negative predictive values of QMPSF for detecting gains were 88% and 97%, respectively. Similarly, the positive and negative predictive values of QMPSF for detecting gene losses were 90% and 97%, respectively.
Allelic deletion of CDKN2A was detected in 9/17 cases using both methods, giving a concordance rate of 100%. Array CGH analysis indicated that loss of CDKN2A gene copy number could result from either a large deletion encompassing the telomeric part of the short arm of chromosome 9 or could be the consequence of a narrow deletion. In 6/9 cases, a CGH log2 ratio < -1.0 indicated a homozygous deletion of CDKN2A, corresponding to a QMPSF ratio lower than 0.45 in all cases (Figure 2 ). 
Frequencies of gain and loss in the overall DLBCL population
Gain and loss frequencies of the ten genes analyzed by the two QMPSF assays are indicated in Table 1 . Some target genes were mainly gained such as MYC, CDKN1B, MDM2, c-REL, or BCL2. By contrast, CDKN2A, TP53, SIM1 and PTPRK were almost exclusively deleted. CDKN2A loss was observed in 36% of DLBCL. In 13 cases, the QMPSF ratio was below 0.45, corresponding to a CGH log2 ratio < -0.5, indicating a homozygous deletion. SIM1 (6q16) and PTPRK (6q22) deletions were more frequently observed in MUM1-positive DLBCL (p=0.004 and 0.008, respectively) and in the non-GCB DLBCL subgroup. c-REL gains were observed in 13/31 (42%) GCB-DLBCL and in 8/46 (17%) non-GCB DLBCL (p=0.02). Gain of BCL2 copy was more frequently observed in the non-GCB subtype. Among the 13 cases with homozygous CDKN2A deletion, 11 belonged to the non-GCB subtype, and two to the GCB subtype (p=0.06). However, some simultaneous gene copy number abnormalities also occurred frequently in the same tumors, even if these gene are not located on the same chromosome. For instance, 11/16 cases (68%) with BCL6 (3q27) gains also had BCL2 (18q21) gains (p=0.0003). Multiple losses of tumor suppressor genes can be observed. For instance, in five cases (6%), concomitant loss of TP53 and CKND2A was observed. Furthermore, CDKN2A allelic loss was associated with SIM1 and PTPRK deletions (p=0.003). The details of allelic status of each gene are indicated in the supplemental data (Online Supplemental Table S2 ). Furthermore, using matched non-tumoral DNA as a control, we confirmed that gene copy number changes were not inherited polymorphisms (data not shown).
Protein expression, TP53 mutation and allelic status
The lack of p16 protein expression was mainly observed in cases characterized by a CDKN2A QMPSF ratio <0.7 ( Figure 2B and Table 1 ). Conversely, gain of BCL2-gene copy number correlated positively with a higher proportion of BCL2-positive cases. A trend for higher MYC protein expression was observed in cases of gain of MYC copies. c-REL expression was detected by immunohistochemistry in seven of the 21 cases (33%) that displayed c-REL gains. Most of the cases (6/7) with both c-REL gain and c-REL protein expression were classified in the GCB subtype, as compared to only one case classified in the non-GCB subtype ( Table 1) . TP53 sequence analysis revealed 11 missense single-base substitutions and one nonsense mutation, distributed in 77 patients. In 5/11 cases, TP53 missense mutations were associated with allelic loss. Overall, cases with allelic loss tended to be more frequently mutated (5/18), as compared to tumors with no TP53 deletion (6/59) (p=0.11). p53 protein accumulation was detected by immunohistochemistry in 7/11 mutated cases and in the 4/5 cases with both TP53 mutations and deletions (Online Supplemental Table S3 ). By contrast, only 9/57 unmutated cases (15%) expressed p53, indicating a strong correlation between TP53 mutations and p53 expression (p=0.001).
Prognostic significance of QMPSF assays
The prognostic value of the QMPSF assays was analyzed for each individual gene or using a scoring system established as the amount of gene number abnormalities detected by a single QMPSF assay. Only gain of CDKN1B (12p13.1) was related to significantly shorter progression-free and overall survival. The 3-year progression-free survival rate was 34% for patients with gain of CDKN1B, (16-46% CI-95%), and 67% (52-79%, CI-95%) for patients with a germline configuration (p=0.001). Given the fact that tumor behavior is considered to be the result of multiple gene alterations, we assessed the additive or synergic effect of each gene gain or loss determined by a single QMPSF assay. Each abnormality was scored as +1 and was included in a scoring system. The addition of four abnormalities, MYC and CDKN1B gains, TP53 and CDKN2A losses, was the most powerful scoring system to predict the outcome. The progression-free and overall survival were significantly shorter for patients with a QMPSF score >1 than for patients whose tumors were scored 0-1. This prognostic value held true for the GCB and the non-GCB subtypes. The score remained significantly predictive of a shorter overall survival in the high risk group and tended to be predictive in the low risk group (Figure 3) . The prognostic value of the score also held true when only patients treated with CHOP/CHOPlike regimens (excluding patients treated with autologous stem cell transplantation or rituximab as frontline therapy) were considered. In this subgroup (n=58), the 3-year progression-free survival rate was 64% (48-77%, CI-95%) for patients with a score of 0-1 and 16% (5-38%, CI-95%) for patients with a high QMPSF score (p<0.001). Similarly, the 3-year overall survival rate was 67% (51-79%, CI 95%) for the low score QMPSF group and 26% (12-49%, CI-95%) for patients with a score > 1 (p=0.001).
A multivariate analysis was performed including International Prognostic Index, QMPSF score and the GCB/non-GCB status. In this model, with variables available for 75 patients, QMPSF was a strong predictor of both progression-free and overall survival (p=0.0084) along with the International Prognostic Index (p=0.0059). Finally, International Prognostic Index and QMPSF were integrated to build a composite score and defined three distinct prognostic groups (Figure 4) . 
Discussion
With the aim of providing a more accessible approach than array CGH, we developed a QMPSF assay for DLBCL. This method has several advantages in comparison to conventional or array CGH. Firstly, the QMPSF assay is a simple, routinely applicable and inexpensive method which requires only a minimal amount of tumor DNA for the simultaneous detection of genomic deletions or gains. Standardization of this method for a wide range of applications in molecular diagnostic laboratories is now conceivable and it should be integrated with others prognostic biomarkers. In contrast to array CGH, this inexpensive method can be used to determine rapidly the frequency of gains or losses of targeted oncogenes or tumor suppressor genes in large cohorts of patients. Secondly, QMPSF is a very flexible method which can be easily upgraded by changing targeted genes or can be dedicated specifically to distinct subtypes of nonHodgkin's lymphoma. Thirdly, conventional CGH and to a lesser extent array CGH give information regarding the whole genome but are still limited by their level of resolution, which corresponds to regions encompassing dozens to hundreds of genes. By contrast using a QMPSF assay, indications regarding gains or losses of a limited number of key genes are obtained at the gene resolution level. However, it should be noted that QMPSF and CGH methods are both dependent on the proportion of tumor cells and may, therefore, be inadequate for detecting somatic defects only present in minor subclones.
Previous studies have reported comparative genome analyses of DLBCL, showing relevant differences in the genomic imbalance patterns of the activated B-cell-like and GCB subgroups. 10, 18, 22 In the present study, we confirmed most of the genomic imbalances previously reported. For instance, it was recently shown that 6q21-22 losses, and 3q27 or 18q21-22 gains were more frequently observed in the activated B-cell-like subtypes, corresponding to PTPRK loss, and BCL6 or BCL2 gains, respectively, detected by QMPSF. 10 A gain of c-REL copy number was observed in 29% of cases, a rate similar to that detected by CGH or by Southern blot. [23] [24] [25] This gain is predominantly but not exclusively observed in the GCB subtype.
2,22 Interestingly, c-REL copy number gain tends to be more frequently associated with protein expression only in the GCB subtype, indicating that c-REL protein deregulation pathways may be distinct in the two DLBCL subtypes. This observation was recently suggested by the correlation between chromosomal copy number changes and mRNA levels, revealing that genomic copy number gains in 2p14-16, 12q12-15, 3q27-qter and 18q21-q22 lead to subtype-specific upregulation of genes located in these regions. 10 Deletions of the CDKN2A gene were detected in 36% of the DLBCL cases. Tagawa and co-workers reported a more frequent loss of 9p21 in the activated B-cell-like group. 11 Here we demonstrated at the gene resolution level that 9p21 loss detected by CGH involved the CDKN2A gene. The lack of p16 ink4a protein expression most frequently observed in cases of gene deletion indicated that this mechanism contributes, possibly in combination with methylation, to the down-regulation of this tumor suppressor gene.
To determine the biological relevance of TP53 deletions detected by QMPSF, TP53 mutation status of the central core binding domain was simultaneously assessed. Interestingly, as reported in a large series of NHL of various histology, we observed that TP53 mutations were mainly present in tumors in which allelic loss had occurred. 26 This observation indicates that p53 mutations play both recessive and dominant roles in lymphoma.
We demonstrated that a single PCR assay, based on the gene copy numbers of TP53, MYC, CDKN2A and CDKN1B, had a prognostic value independent of the International Prognostic Index and added to its predictive power. A validation of our QMPSF score in an independent set of patients treated uniformly with regimens including rituximab is now necessary. It is likely that genes that are predictive in DLBCL mainly treated first line without rituximab will have a different impact in patients treated with rituximab plus chemotherapy. 27, 28 Because our approach is very flexible, the QMPSF assay can be easily upgraded and adapted to incorporate additional genes more predictive in this setting. For instance, it was shown that patients whose tumors have 3p11-12 gains have a worse prognosis and new potential tumor suppressor genes have been recently identified. 10, 29 These data should be integrated to establish a second generation QMPSF assay to predict the outcome of lymphoma treated by immunochemotherapy.
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